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Abstract
Despite the important role of the carboxyl-terminus (Ct) of the activated brain cannabinoid 
receptor one (CB1) in the regulation of G protein signaling, a structural understanding of 
interactions with G proteins is lacking. This is largely due to the highly flexible nature of the CB1 
Ct that dynamically adapts its conformation to the presence of G proteins. In the present study, we 
explored how the CB1 Ct can interact with the G protein by building on our prior modeling of the 
CB1-Gi complex (Shim J-Y, Ahn KH, Kendall DA. The Journal of Biological Chemistry 
2013;288:32449-32465) to incorporate a complete CB1 Ct (Glu416Ct–Leu472Ct). Based upon the 
structural constraints from NMR studies, we employed ROSETTA to predict tertiary folds, 
ZDOCK to predict docking orientation, and molecular dynamics (MD) simulations to obtain two 
distinct plausible models of CB1 Ct in the CB1-Gi complex. The resulting models were consistent 
with the NMR-determined helical structure (H9) in the middle region of the CB1 Ct. The CB1 Ct 
directly interacted with both Gα and Gβ and stabilized the receptor at the Gi interface. The results 
of site-directed mutagenesis studies of Glu416Ct, Asp423Ct, Asp428Ct, and Arg444Ct of CB1 Ct 
suggested that the CB1 Ct can influence receptor-G protein coupling by stabilizing the receptor at 
the Gi interface. This research provided, for the first time, models of the CB1 Ct in contact with 
the G protein.
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Introduction
Agonist-stimulated G protein-coupled receptors (GPCRs) interact with G proteins and 
trigger a series of internal G protein-dependent signaling events (for a review, see ref. 1). 
These agonist-stimulated GPCRs are also phosphorylated by GPCR kinases (GRKs)2 which 
facilitate G protein uncoupling and arrestin recruitment, leading to receptor desensitization 
and internalization3-6. The X-ray crystal structure of the agonist-bound β2-adrenergic 
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receptor (β2AR) in complex with Gs7 revealed the molecular details of the GPCR-G protein 
interaction where the C-terminal helix α5 of Gα binds to the intracellular (IC) core of the 
receptor. A recent X-ray crystal structure of the finger loop peptide of rod photoreceptor 
arrestin (S-arrestin) bound to rhodopsin8 showed that arrestins also utilize the same receptor 
IC core as a key contact. This suggests that G proteins and arrestins compete for a common 
binding site on the activated receptor. Although little is known about the molecular details of 
how a GPCR interacts with GRKs, partly due to relatively low affinity for the formation of 
the GPCR-GRK complex9, it has been proposed that the N-terminal helix of the kinase 
domain of GRKs also interact with the same IC core of the activated receptor10.
Deletion or mutation of the cytoplasmic carboxyl-terminus (Ct) in GPCRs impaired not only 
G protein coupling but also internalization and desensitization11-16, suggesting that the 
receptor Ct plays a crucial role in the regulation of G protein signaling. Ct in GPCRs is also 
an important site for the interactions with GRKs and arrestins2,4,5. A very recent X-ray 
crystal structure of a constitutively active form of rhodopsin bound to mouse visual 
arrestin17 revealed that the Ct forms an interface patch for the interaction of rhodopsin with 
arrestin, which was validated by extensive cross-linking between the N-terminus of arrestin 
and Ct of rhodopsin. It was suggested that the phosphorylated Ct of the receptor can form 
tight interactions with the positively charged pockets of the N-terminus of arrestin, thus 
emphasizing the critical role of Ct. Similar charge-charge interactions between the 
phosphorylated Ct peptide and positively charged resides of β-arrestin-1 were also suggested 
in the X-ray crystal structure of the phosphorylated Ct peptide of the human V2 vasopressin 
receptor (V2R) bound to β-arrestin-118. It is remarkable that different regions of the receptor 
Ct play distinct roles in signal regulation. For example, it was shown in the human 
neuropeptide Y receptor type 2 (Y2R) that the N-terminal region of the Ct was involved in 
internalization in a β-arrestin-independent manner, the C-terminal region of the Ct was 
involved in internalization in a β-arrestin-dependent manner, and the middle region of Ct 
was involved in regulating the activity of the first two regions13. It was also shown in the 
β2AR that the N-terminal region of the Ct contained the GRK6 phosphorylation sites 
responsible for β-arrestin-mediated ERK activation, while the C-terminal region of Ct 
contained the GRK2 phosphorylation site responsible for internalization19. Similarly, 
mutagenesis studies of the μ opioid receptor (MOR) Ct indicated that different kinases 
phosphorylated different Ser residues20. These results suggest that recruitment of specific 
types of GRKs and β-arrestins is dictated by the conformation of the GPCR carboxyl-
terminus. Thus, the finding that carvedilol, a β-arrestin-biased ligand, induced 
phosphorylation of β2AR only by GRK6, while isoproterenol, a non-biased ligand, induced 
phosphorylation of β2AR both by GRK2 and GRK619 suggests that the ligand likely puts 
the receptor in a distinct conformation that induces a specific profile of phosphorylation of 
the Ct.
The brain cannabinoid receptor one (CB1) is a rhodopsin subfamily (class A) GPCR found 
predominantly in the central nervous system (CNS)21. As in many GPCRs, CB1 Ct has been 
shown to be important for G protein signal regulation (for review, see ref. 22). A series of 
truncation mutants were studied to examine the functional importance of CB1 Ct. Deletion 
of the entire Ct including the juxta-membrane eighth helix (H8) that follows the 
transmembrane (TM) helical domain resulted in abolished Ca2+ channel inhibition23. 
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Moreover, the removal of Arg400H8 from a peptide analog of H8 of the CB1 receptor 
exhibited a 6-fold reduction in Gi affinity and an almost complete loss of the inhibitory 
effect on adenylyl cyclase activity24. These results suggest that H8 plays an important role in 
G protein coupling to the CB1 receptor. Our recent computational modeling study of the 
CB1-Gi complex identified Arg400H8 as one of the key CB1 contact residues with the C-
terminal helix α5 of Gα at the receptor-Gi interface25. Interestingly, truncation of the Ct at 
position Thr418Ct immediately after H8 exhibited an increase in constitutive activity and G 
protein sequestration26, suggesting that CB1 Ct after H8 plays a role in regulating G protein 
activation. Different sections of CB1 Ct play distinct roles in signal regulation. It was 
observed that Ala mutations of Ser425Ct and/or Ser429Ct at the N-terminal region of CB1 Ct 
resulted in significant decreases (> 50%) in GRK3- and β-arrestin 2-mediated 
desensitization27 and delayed tolerance28. Furthermore, biochemical studies of the 
truncation and multiple Ala mutations indicated that Ser and Thr residues (Thr460Ct–
Ser468Ct) at the C-terminal region of CB1 Ct were important for receptor internalization29.
While increasing information is available for the structure of extracellular (EC) and TM 
domains of GPCRs, only limited information is available for the structure of GPCR Ct. No 
X-ray crystal structure of any GPCR, where the receptor Ct is complete, has ever been 
determined, since the receptor structure beyond H8 is frequently disordered due to its 
intrinsic flexibility30. The X-ray crystal structures of rhodopsin (pdb codes 1U19 and 
3AYN)31,32 revealed that the Ct was folded under the receptor IC surface, particularly near 
H8. In contrast, the conformation of β2AR Ct was suggested to be extended and 
unstructured from fluorescence resonance energy transfer (FRET) studies33, which would be 
important for inducing distinct conformations by different ligands19.
Without having any X-ray crystal structure of CB1 Ct, Ahn et al.34 determined the NMR 
structure of the unphosphorylated CB1 Ct peptide (Arg400H8–Leu472Ct). They identified a 
helix (Ala440Ct–Met461Ct) called the ninth helix (H9) in the middle region (Table 1). Two 
additional NMR structures of phosphorylated CB1 Ct peptides in complex with human β-
arrestin-1 have been reported. The NMR structure of the diphosphorylated CB1 Ct peptide 
(residues Thr418Ct–Asn437Ct) in complex with β-arrestin-135 showed two helical segments 
(Leu422Ct–Gly427Ct and Asp428Ct–Leu432Ct) (Table 1). A more recent NMR study on the 
pentaphosphorylated, extreme C-terminal peptide (residues Thr453Ct–Leu472Ct) in complex 
with β-arrestin-136 revealed the presence of a helical segment (Asp466Ct–Glu470Ct) (Table 
1). These NMR-determined secondary structures of CB1 Ct are intriguing in that well-
defined secondary structures and/or folds can be induced from the intrinsically disordered 
CB1 Ct upon interaction with its cognate binding proteins (the G protein, GRKs and 
arrestin) and in that the nature of phosphorylation would significantly alter the secondary 
structure and fold, and thereby the function, of CB1 Ct.
Although these NMR studies34-36 provided invaluable insight into the CB1 Ct peptide 
structure, it is necessary to determine the structure of CB1 Ct in contact with the G protein 
to gain structural information about the potential role of CB1 Ct in G protein signaling. In 
this study, we elucidated the plausible interactions of CB1 Ct with the G protein by building 
on our prior modeling effort of the CB1-Gi complex lacking CB1 Ct (CB1(noCt)-Gi)25. The 
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results suggested that the CB1 Ct can influence receptor-G protein coupling by stabilizing 
the receptor at the Gi interface.
Methods
Cell Culture and Membrane Preparation
HEK293 cells were transiently transfected with the wild-type or mutant CB1 receptor using 
the calcium phosphate precipitation method as described previously37. One day after 
transfection, membrane preparations were made38. This involved washing the cells with 
phosphate buffered saline (PBS) and resuspending them in a solution of PBS with 1% (v/v) 
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). The cells were subjected to 
nitrogen cavitation at 750 psi using a Par cell disruption bomb. The disrupted cells were then 
centrifuged at 500 × g for 10 min at 4°C and the supernatant was extracted. The supernatant 
was then centrifuged at 100,000 × g for 45 min at 4°C and the membrane pelleted. The 
membrane pellet was resuspended in TME buffer (25 mM Tris-HCl, 5 mM MgCl2, and 1 
mM EDTA, pH 7.4) with 7% (w/v) sucrose and the protein concentration was determined 
using the Bradford assay39.
Ligand Binding Assay
Competition binding assays were performed as described previously40. Briefly, 7.5 μg of 
wild-type or mutant CB1 receptor membrane preparations were incubated for 60 min with 
increasing concentrations of CP55,940 ranging between 100 pM and 10 μM in the presence 
of 2 nM [3H]CP55,940 (141 Ci/mmol, PerkinElmer Life Sciences (Boston, MA)) as tracer in 
a total volume of 200 μl of TME buffer containing 0.1% fatty acid-free BSA. Nonspecific 
binding was assessed using 1 μM unlabeled CP55,940. The reaction was terminated by the 
addition of 250 μl TME buffer containing 5% BSA followed by filtration with a Brandel cell 
harvester through Whatman GF/C filter paper and the bound radioactivity measured. Ligand 
depletion was avoided and the bound ligand was kept less than 10% of the total.
GTPγS Assay
Briefly, 8.5 μg of membrane preparation was tested with at least nine different 
concentrations of unlabeled CP55,940 ranging between 100 pM and 10 μM as described 
previously40. The membrane preparations were incubated with 0.1 nM [35S] GTPγS (1,250 
Ci/mmol; PerkinElmer Life Sciences, Boston, MA), 3 μM GDP (Sigma, St. Louis, MA), 
0.1% w/v BSA and varying concentrations of unlabeled CP55,940 in a total volume of 200 
μl of GTPγS binding buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA and 
100 mM NaCl) for 60 min. Nonspecific binding was determined with 10 μM unlabeled 
GTPγS (Sigma, St. Louis, MA). The reaction was terminated by filtration through Whatman 
GF/C filters followed by washing with ice cold TME buffer and the bound radioactivity 
determined.
Data Analysis
All ligand binding and GTPγS assays were carried out in duplicate and at least three 
independent experiments were performed. Data are presented as the mean ± S.E. for the Ki 
values, basal levels and CP55,940-induced Emax values and the median and the 
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corresponding 95% confidence limits for the EC50 values. The data collected were subjected 
to nonlinear regression using Prism 6.0 (Graphpad Software Inc., San Diego, CA) as 
previously described41. Comparison was done using analysis of variance (ANOVA) between 
the wild type and the mutant receptors followed by Bonferroni’s post hoc test and p < 0.05 
was considered statistically significant.
Generation of Tertiary Folds of the CB1 Carboxyl-terminus
Using ROSETTA’s comparative modeling protocols42,43, we sampled the conformational 
space related to the sequence of the CB1 Ct peptide (Glu416Ct–Leu472Ct) and obtained the 
structural backbone of the CB1 Ct peptide from a fragment library extracted from known 
protein structures using Monte Carlo sampling44. We also sampled side chain conformation 
of the CB1 Ct peptide using the rotamer database45 and obtained the best combination of 
side chain angles by Monte Carlo simulated annealing. Among the highest scored 
ROSETTA-predicted models, we selected five models that agreed with NMR data34-36.
Docking of CB1 Ct to the CB1-Gi Complex
Each of the five ROSETTA-predicted models of the CB1 Ct peptide was docked to our prior 
model of the CB1-Gi complex (CB1(noCt)-Gi)25, where the CB1 receptor was truncated at 
the palmitoylated Cys415H8 at the end of H8, using the ZDOCK (version 3.0.2) server46. We 
examined the ZDOCK models of the CB1 Ct peptide in the CB1-Gi complex and selected 
the best model using the following criteria: i) the fifty best scoring ZDOCK models of the 
CB1 Ct peptide in the CB1-Gi complex were selected; ii) the distance between the C-
terminal end residue (Cys415H8) of the CB1 receptor and the N-terminal end residue 
(Glu416Ct) of the docked CB1 Ct peptide should be less than 10 Å, a loose distance criteria 
between these residues for the formation of the amide bond in the following step for 
completing the receptor Ct (see below); and iii) the docked CB1 Ct peptide should not be in 
unfavorable contacts with any part of both the receptor and the G protein. We repeated this 
docking procedure for all of the five ROSETTA-predicted models of the CB1 Ct peptide. 
The best two ROSETTA-predicted models of the CB1 Ct peptide in the CB1-Gi complex 
that met the above criteria were selected. We called these two plausible models of CB1 Ct in 
the CB1-Gi complex, ACt and BCt.
Simulations of the CB1-Gi Complex
Simulations of the CB1 Ct peptide and the CB1-Gi complex (CB1(noCt)-Gi)—
Each of the CB1 Ct peptides, ACt and BCt, were inserted into our prior model of the CB1-Gi 
complex (CB1(noCt)-Gi) in a fully hydrated 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) lipid bilayer25. The N-terminus of the CB1 Ct peptide was capped 
by an acetyl group, while the C-terminus was retained as a free carboxylate form. Any water 
molecule within 1.0 Å of the newly added CB1 Ct peptide was removed. The system was 
then electrically neutralized (to ~0.15 M NaCl) using the Solvate plugin in VMD47. A total 
of ~220,000 atoms, including the cannabinoid agonist (−)-11-hydroxydimethylheptyl-Δ8-
tetrahydrocannabinol (HU210)-bound whole CB1 receptor, the GDP-bound Gi protein, 73 
Na+ and 69 Cl− ions, ~51,300 water molecules, and ~360 POPC molecules, resulted in a 
system of the CB1-Gi complex (Fig. 1A i and 1B i) in a simulation box of approximately 90 
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× 130 × 180 Å3. The entire system of the CB1-Gi complex was subjected to energy 
minimization (3,000 iterations). This was followed by two distance-restrained MD 
simulations at 310 K in the NPT ensemble: The distance between the backbone carbonyl 
oxygen atom of Cys415H8 in the CB1 receptor and the backbone amide nitrogen atom of 
Glu416Ct in the CB1 Ct peptide was harmonically constrained (20.0 kcal/molÅ2) to 10 Å for 
the first 5 ns of the simulation and to 5 Å for the second 5 ns of the simulation.
Simulations of the CB1-Gi complexes CB1(ACt)-Gi and CB1(BCt)-Gi—For the 
resulting system, we created an amide bond between the receptor C-terminal Cys415H8 in 
the CB1-Gi complex model and the N-terminal Glu416Ct of the CB1 Ct peptide to complete 
the receptor within the CB1-Gi complex. Then, the entire system of the CB1-Gi complex 
was subjected to an energy minimization (3,000 iterations). This was followed by a 
simulation at 310 K in the NPT ensemble to obtain an all-atom, solvent-equilibrated model 
of the CB1-Gi complex. By repeating this step for each of ACt and BCt, we obtained two 
distinct models of CB1 Ct in the CB1-Gi complex, CB1(ACt)-Gi and CB1(BCt)-Gi.
Simulation Protocol
All simulations were performed using the NAMD simulation package (ver. 2.7 Linux-
x86_64)48, using CHARMM36 force field parameters for proteins with the ϕ/ψ angle cross-
term map correction49,50 and lipids51, and the TIP3P water model52. The temperature was 
maintained at 310 K through the use of Langevin dynamics53 with a damping coefficient of 
1/ps. The pressure was maintained at 1 atm by using the Nosé-Hoover method54 with the 
modifications as described in the NAMD user’s guide. The van der Waals interactions were 
switched at 10 Å and zero smoothly at 12 Å. Electrostatic interactions were treated using the 
Particle Mesh Ewald (PME) method55. A pair list for calculating the van der Waals and 
electrostatic interactions was set to 13.5 Å and updated every 10 steps. A multiple time-
stepping integration scheme, the impulse-based Verlet-I reversible reference system 
propagation algorithm method56, was used to efficiently compute full electrostatics. The 
time step size for integration of each step of the simulation was 1 fs.
Results
Structural Stability of CB1 Ct in the CB1-Gi Complex
Two all-atom, solvent-equilibrated models of the CB1-Gi complex, CB1(ACt)-Gi and 
CB1(BCt)-Gi, at the end of 205 ns simulations are shown in Fig. 1A i and 1B i respectively. 
At the end of the simulations, no residue of ACt or BCt was in the disallowed region on the 
Ramanchandran plot as defined by PROCHECK57. To measure the structural stability of 
CB1(ACt)-Gi and CB1(BCt)-Gi, the root-mean-square deviations (RMSDs) were calculated 
over the performed simulations (Fig. 1A ii and 1B ii). The RMSD values of both models of 
the whole complex continued to evolve without being fully stabilized by the end of the 
simulation. However, the RMSD values of ACt in CB1(ACt)-Gi indicated that the CB1 Ct 
was fully stabilized after 175 ns of the simulation (Fig. 1A ii). At ~175 ns of the simulation, 
the RMSD values of ACt were slightly increased when part of the structural motifs of ACt 
was rearranged in response to the extreme C-terminal end residue Leu472Ct that became 
deeply inserted into the CB1-Gα/Gβ interfacial region and formed tight salt bridges to 
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R336IC3 and R340IC3 of the CB1 receptor (Fig. 1A iii). In contrast to ACt in CB1(ACt)-Gi, 
BCt in CB1(BCt)-Gi was not completely stabilized at the end of 205 ns simulations (Fig. 1B 
ii). In BCt, the highly flexible C-terminal end residue Leu472Ct that traveled over 40 Å and 
formed tight salt bridges to R405H8 of the CB1 receptor near the TM7/H8 junction (Fig. 1B 
iii).
Molecular Features of the CB1 Ct
ACt in CB1(ACt)-Gi contained one helical segment (H9) in the middle region adjacent to 
three anti-parallel β-bridges in both the N- and C-terminal regions (Fig. 1A i), while BCt in 
CB1(BCt)-Gi contained H9 in the middle region and another helical segment in the N-
terminal region (Fig. 1B i). In both models, H9, largely in agreement with the NMR-
structure of the CB1 Ct peptide34 (Table 1), was in an amphipathic alignment: the nonpolar 
face was buried and participated in forming the extensive hydrophobic cluster (Fig. 2A), 
while the polar face was exposed to the solvent. The detailed interactions of the CB1 Ct 
within the CB1-Gi complex are listed in Table 2. Throughout the simulations of CB1(ACt)-
Gi and CB1(BCt)-Gi, H9 in the middle region of CB1 Ct were well retained. One of the 
reasons that the helical contents of H9 in the present models were more limited (<15 
residue-long) compared with the NMR-determined structure (22 residue-long)34 was that H9 
in the present models of CB1 Ct was stabilized in an intact receptor environment, while the 
NMR-determined structure was stabilized in a dodecylphospho-choline (DPC) micelle 
environment34, a media favorable for helical induction. BCt agreed with the NMR structure 
of the CB1 Ct peptide35 with respect to the presence of an additional helix on the N-terminal 
region of CB1 Ct (Table 1). In CB1(BCt)-Gi, this additional helix was created during the 
simulation (Fig. 2B), suggesting the N-terminal region of CB1 Ct has a tendency to have a 
helical structure. None of the present models of CB1 Ct predicted the presence of the helical 
segment at the C-terminal region identified in one NMR structure36 (Table 1). This may be 
due to the fact that the NMR structure was multi-phosphorylated and in complex with 
arrestins, while the present structure was unphosphorylated and in complex with the G 
protein.
Flexibility of CB1 Ct in the CB1-Gi Complex
To examine the intrinsic flexibility of CB1 Ct in the CB1-Gi complex, we calculated the 
variance of every atom position over the trajectories of the last 20 ns of the simulation for 
each of CB1(ACt)-Gi and CB1(BCt)-Gi. The RMS fluctuation (RMSF) plots (Fig. 3) 
indicated that CB1 Ct was one of the most flexible regions in the CB1-Gi complex. The only 
region equally flexible to CB1 Ct was the 40 residue-long third IC loop (IC3) of the CB1 
receptor and the α-helical domain of Gα that is crucial for G protein activation1. 
Comparison of the RMSF plots of CB1(ACt)-Gi and CB1(BCt)-Gi revealed that the middle 
region of ACt highly fluctuated compared with that of BCt (Fig. 3). Since the N-terminal 
region is directly connected to the middle region, fluctuations in the N-terminal region 
would contribute to fluctuations in the middle region. Thus, the less structured N-terminal 
region of ACt in CB1(ACt)-Gi compared with the more structured N-terminal region of BCt 
in CB1(BCt)-Gi (Table 1) would give rise to high fluctuations in the middle region of ACt in 
CB1(ACt)-Gi.
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Site-directed Mutagenesis Studies of Glu416Ct, Asp423Ct, Asp428Ct, and Arg444Ct of CB1 
Ct in the CB1-Gi Complex
To investigate the potential role of CB1 Ct in the G protein coupling activity, we chose four 
amino acid residues, Glu416Ct, Asp423Ct, Asp428Ct, and Arg444Ct, from the CB1 Ct which 
were suggested to be important for intra- or inter-molecular interactions in stabilizing the 
CB1-Gi complex (Table 2). Both Glu416Ct and Asp428Ct were suggested to form charged-
charged intra-molecular interactions with Arg409H8 in both CB1(ACt)-Gi and CB1(BCt)-Gi 
(Table 2), stabilizing H8 of the receptor. Asp428Ct was also involved in stabilizing the 
structured motifs in the middle region of the CB1 Ct in CB1(ACt)-Gi. We chose Asp423Ct, 
which was suggested to have inter-molecular interactions with Gβ in both CB1(ACt)-Gi and 
CB1(BCt)-Gi (Table 2). Arg444Ct was suggested to have intra-molecular interactions with 
Glu447Ct, stabilizing the middle region α-helix in CB1(ACt)-Gi and with Asp466Ct, 
stabilizing the C-terminal end region in CB1(BCt)-Gi (Table 2). These residues were 
frequently involved in tight salt bridges in the present models of the CB1-Gi complex (Table 
2), suggesting that the disruption of these residues may cause destabilization of CB1 Ct.
In ligand binding experiments, the four mutated receptors showed no difference in the Ki 
values for binding of CP55,940 compared to wild-type CB1 (Table 3 and Fig. 4A), 
suggesting no impact of these mutations on the folding, conformational stability and 
expression of these receptors. These mutated receptors were then analyzed for their G 
protein coupling activity. First, we evaluated the EC50 values for CP55,940-induced G 
protein coupling. None of the mutated receptors showed any significant difference in the 
concentration of CP55,940 (EC50 values) needed for G protein coupling compared to the 
wild-type CB1 receptor (Table 3 and Fig. 4B). Second, we analyzed the level of G protein 
coupling for basal activity (CB1 exhibits some constitutive activity in the absence of 
ligand58,59). There was no significant impact on the basal level of GTPγS binding for the 
Glu416CtAla receptor suggesting that G protein coupling was essentially the same as the 
wild-type CB1 receptor. Interestingly, the basal levels of Asp423CtAla and Asp428CtAla 
receptors were significantly higher compared to the wild-type CB1 receptor. In contrast, the 
basal level of Arg444CtAla receptor was not significantly different from the wild-type CB1 
receptor (Table 3 and Fig. 4B). Third, we evaluated the impact of these mutations on the 
Emax levels for G protein coupling following CP55,940 treatment. Treatment with agonists 
like CP55,940 allows the receptor to adopt an active confirmation, thus revealing maximal G 
protein coupling by that ligand as depicted by the Emax levels. No change in the Emax levels 
was observed for Glu416CtAla compared to the wild-type CB1 receptor, suggesting that this 
residue may be less important for G protein coupling. Interestingly, the Emax level for the 
Arg444CtAla receptor was somewhat lower than the wild-type CB1 receptor suggesting that 
G protein coupling is impaired by this mutation. On the other hand, the Emax levels for the 
Asp423CtAla and Asp428CtAla receptors following CP55,940 treatment, were higher than 
the wild-type CB1 receptor. Thus, this suggests that the residue replacements by these 
mutations promote G protein coupling, which is reflected in both basal and CP55,940-
induced levels. Overall, none of the mutations impacted the concentration of CP55,940 
needed to get half maximal G protein coupling though some did impact the maximum extent 
of G protein coupling suggesting the efficacy of G protein coupling was altered.
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CB1 Ct has been shown to be important for G protein signal regulation (for review, see ref. 
22). Since the CB1 Ct is highly flexible, its position and conformation easily adapt to the 
presence of G proteins. In order to understand the role of CB1 Ct in G protein coupling, we 
explored the structure of the 57-residue (Glu416Ct–Leu472Ct) CB1 Ct in the CB1-Gi 
complex. Full conformational sampling of CB1 Ct is almost impossible due to the large 
number of degrees of freedom. Earlier work showed that the 25 residue-long rhodopsin Ct 
was not well sampled by 26 independently constructed simulations of rhodopsin embedded 
in an explicit lipid membrane on the 100 ns time scale59. Enhanced sampling techniques, 
such as replica exchange molecular dynamics (REMD)60,61, have been widely used for 
enhancing the conformational sampling of MD simulations. However, even an explicit 
solvent system for a small protein (~ 20 residue-long) requires more than 40 replicas for 
efficient REMD62. Moreover, the simulations time should be long enough for each trajectory 
to cover the entire conformational space as well as the entire temperature space63.
Exhaustive sampling was not used in the present study because we aimed to obtain a 
plausible and reasonable model view for the structure of the contact region of the CB1 Ct 
with the G protein. To mitigate the problem in conformational sampling, we employed 
ROSETTA to predict tertiary folds of the CB1 Ct peptide, ZDOCK to predict docking 
orientations of CB1 Ct considering the structural constraints imposed as part of the CB1 
receptor in the CB1-Gi complex. ROSETTA has been reputed to predict high-probability 
structures of protein domains with fewer than 200 amino acid de novo64, while ZDOCK has 
demonstrated its high performance in predicting protein–protein docking orientation with > 
60% success in Critical Assessment of Predicted Interactions (CAPRI)65. Owing to the 
motion of the intrinsically flexible CB1 Ct, the trajectories produced by independent 
simulations of two distinct models of CB1 Ct in two different regions of the configuration 
space of the CB1-Gi complex appeared to enable sampling of regions that otherwise would 
be little visited. For example, in CB1(BCt)-Gi, the performed simulations enabled freely 
visiting most of the region of Ct fold (i.e. the CB1-Gα/Gβ interface under the receptor IC 
surface) (Fig. 2B).
RMSDs calculated only for secondary structure were used to measure the structural stability 
of CB1(ACt)-Gi and CB1(BCt)-Gi. It appeared that the structural motifs in the middle region 
played a pivotal role in determining the overall stability of CB1 Ct in the CB1-Gi complex. 
However, the stability of the structural motifs in the middle region appeared to be influenced 
by the highly flexible C-terminal region that is tethered to these structural motifs. Indeed, the 
structural motifs in the middle region were frequently rearranged adapting to the formation 
of tight salt bridges by the extreme C-terminal end residue Leu472Ct at the CB1-Gα/Gβ 
interfacial region (Fig. 1A i and 1B i). Possibly due to the highly flexible nature of the Gα-
Gβ interfacial region as well as the unstructured regions of CB1 Ct (both the N-terminal and 
C-terminal regions), substantially long simulations of the present models of the CB1-Gi 
complex are needed in future studies for a full structural convergence of CB1 Ct.
Intrigued by a strong tendency of the extreme C-terminal end residue Leu472Ct to form salt 
bridges to the CB1-Gα/Gβ interfacial region (Fig. 1A iii and 1B iii), we examined the 
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electrostatic surface map of the CB1-Gi complex (Fig. 2C i). It revealed that the CB1-Gα/
Gβ interfacial region was electrostatically highly positive. Since the extreme C-terminal 
residue Leu472Ct was free to move, the negatively charged carboxylate moiety of Leu472Ct 
was facilitated to come in close proximity to this highly electrostatically-positive receptor-
Gα/Gβ interfacial region (Fig. 2C i). The electrostatic surface map of the CB1-Gi complex 
also revealed that the Gβ region that formed one of the main contacts with the structural 
motifs in the middle of CB1 Ct was electrostatically highly negative (Fig. 2C i). It was 
indicated that the electrostatic surface map of the structural motifs in the middle region of 
BCt was poorly matched to the electrostatically negative Gβ region (Fig. 2C ii), suggesting 
that BCt in CB1(BCt)-Gi was not close to a structural convergence (Fig. 1B ii).
A combined analysis of the computational models of the CB1 Ct and the results of site-
directed mutagenesis studies of Glu416CtAla, Asp423CtAla, Asp428CtAla and Arg444CtAla 
mutant receptors suggested that the CB1 Ct can influence receptor-G protein coupling by 
stabilizing the receptor at the CB1-Gi interface. 1) Interaction with the receptor at the Gα 
interface. The CB1 Ct can influence receptor-G protein coupling by stabilizing the receptor 
at the Gα interface, as suggested by the mutagenesis results of Arg428CtAla mutant receptor. 
Similarly, the carboxylate of Leu472Ct of the CB1 Ct appeared to stabilize the receptor at the 
Gα interface (Fig. 1B i and ii). 2) Interaction with Gα. It was shown that the CB1 Ct 
commonly formed a couple of charge-charge interactions with Gα (Table 2), which could 
affect G protein coupling. 3) Interaction with Gβ. The CB1 Ct can exert its role in receptor-
G protein coupling indirectly through the interactions with Gβ, as suggested by the 
mutagenesis results of Asp423CtAla mutant receptor. 4) Intra-molecular interaction 
within CB1. The intra-molecular interactions within CB1 that stabilize the CB1 Ct are also 
indirectly important for maintaining the conformation of CB1 that forms a complex with G 
protein, as suggested by the Arg444CtAla mutant receptor. Overall, it appeared that the CB1 
Ct can influence receptor-G protein coupling through a combination of different ways of 
stabilizing the receptor at the CB1-Gi interface.
In summary, we explored how the CB1 Ct can interact with G protein. A combined analysis 
of the two distinct models of CB1 Ct suggested that the CB1 Ct can influence receptor-G 
protein coupling by stabilizing the receptor at the CB1-Gi interface. This research provided, 
for the first time, models of CB1 Ct in contact with the G protein.
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β2AR β2 adrenergic receptor
FRET fluorescence resonance energy transfer
MD molecular dynamics
HEK293 human embryonic kidney cell
PBS phosphate-buffered saline
TME Tris/Mg2+/EDTA
GRK G protein-coupled receptor kinases
ERK extracellular signal-regulated kinases
GTPγS guanosine 5′-3-O-(thio)triphosphate




Y2R neuropeptide Y receptor type 2
V2R V2 vasopressin receptor
MOR the μ opioid receptor
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
DPC dodecylphosphocholine
PME Particle Mesh Ewald
PAL palmitoyl moiety
GER geranylgeranyl moiety
RMSDs the root-mean-square deviations
RMSF root-mean-square fluctuation
Ct carboxyl-terminus
CNS central nervous system
CAPRI critical assessment of predicted interactions
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VMD visual molecular dynamics
APBS adaptive Poisson-Boltzmann solver
REMD replica exchange molecular dynamics
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Figure 1. Two simulation systems of the CB1-Gi complex, CB1(ACt)-Gi (A) and CB1(BCt)-Gi 
(B), at the end of 205 ns simulations
(i) The CB1 receptor is represented in red cartoon, while Gi is represented in grey cartoon. 
CB1 Ct with the structural motifs (α-helix, purple; β-sheet, yellow; turn, cyan; and coil, 
white) in the middle region are indicated by a box. PALs, which are covalently bonded to 
Cys415H8 of the CB1 receptor and Cys3Gαi, and GER, which is covalently bonded to 
Cys68Gγ, are represented by green sticks. The CB1 agonist HU210 bound to the receptor, 
GDP bound to Gα, and the CB1 Ct extreme end residue Leu472Ct are represented by space-
filling (atom-type). Lipids and water molecules are represented as lines (atom-type), while 
ions (Na+ in cyan and Cl− in yellow) are represented as balls. The α-helical domain of Gα, 
whose movements are crucial for G protein activation, is indicated by a dotted circle. Lipid 
and water hydrogen atoms are omitted for clarity. Color coding for atoms: C, cyan; N, blue; 
O, red; and S, yellow. (ii) RMSD values of the CB1-Gi complex, for the whole complex (in 
black), for the CB1 receptor (in red), for Gα (in green), for Gβ (in blue), for Gγ (in 
orange), and CB1 Ct (in magenta), calculated by RMS fitting of the coordinates taken during 
the simulation to the initial coordinates, with respect to the backbone Cα atoms of secondary 
structure. (iii) Strong attractions between the CB1-Gα/Gβ interfacial region and the Ct end 
residue Leu472Ct in CB1(ACt)-Gi, measured by side chain distances of Leu472Ct(OCO21)–
Arg336Ct(Nη1) (black), Leu472Ct(OCO22)–Arg336Ct(Nη2) (red), and Leu472Ct(OCO22)–
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Arg340Ct(Nη1) (green) and in CB1(BCt)-Gi, measured by side chain distances of 
Leu472Ct(OCO21)–Arg405Ct(Nη2) (black) and Leu472Ct(OCO22)–Arg405Ct(Nη1) (red).
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Figure 2. Molecular features of the CB1 Ct
A. Hydrophobic clusters centered at H9 in (i) ACt in CB1(ACt)-Gi and (ii) BCt in CB1(BCt)-
Gi. Hydrophobic residues forming the clusters along with the extreme C-terminal end 
residue Leu472Ct are represented by space-filling (atom-type). B. The development of the 
second helix in the N-terminal region of BCt in CB1(BCt)-Gi examined by snapshots taken 
at different times of the simulation: 0 ns, 50 ns, 100 ns, 150 ns, and 200 ns. C. The Poisson–
Boltzmann electrostatic potential map of the CB1-Gi complex, calculated using the APBS 
web server67. (i) The surface of the CB1-Gi complex is rendered in blue and red to illustrate 
electrostatically positive and negative regions, respectively, in the APBS potential data 
ranging from +4 to −4. (ii) The surfaces of ACt in CB1(ACt)-Gi and BCt in CB1(BCt)-Gi in 
the middle are rendered in blue and red to illustrate electrostatically positive and negative 
regions, respectively, in the APBS potential data ranging from +4 to −4. The surface of the 
CB1 Ct interface to Gβ on the right was obtained by rotating the CB1 Ct 180° about the z 
axis. The dotted circles indicate the region of Gβ where the electrostatic potential surface is 
highly negative.
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Figure 3. Inherent flexibility in the CB1 Ct
RMSF plots of CB1(ACt)-Gi (in black), CB1(BCt)-Gi (in red), and CB1(noCt)-Gi24 (in 
green), obtained by calculating the variance of every atom position over the trajectories of 
the last 20 ns of the simulation. CB1 Ct is square-marked in red.
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Figure 4. Site-directed mutagenesis studies of CB1 Ct in the CB1-Gi complex
A. Competition binding of the agonist CP55,940 using [3H]CP55,940 as tracer. Non-specific 
binding was determined in the presence of 1 μM unlabeled CP55,940 for competition 
binding. B. CP55,940-induced [35S]GTPγS to assess G protein coupling. 10 μM unlabeled 
GTPγS was used. In all cases, cell membranes expressing the wild-type CB1 receptor (ο), 
Glu416CtAla (■), Asp423CtAla (▲), Asp428CtAla (▽) or R444CtAla (◆) mutated receptors 
were evaluated. Data points represent the mean ± S.E. (error bars) of at least three 
independent experiments performed in duplicate.
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Table 1
The secondary structure analysis for the CB1 Ct (Glu416Ct-Leu472Ct) in the two distinct models ACt in 
CB1(ACt)-Gi and BCt in CB1(BCt)-Gi, in comparison with the NMR-predicted structures of the CB1 Ct 
peptides. The residues used in the present site-directed mutagenesis studies are indicated in bold. The segment 
that showed a close correlation with the α-helical domain of Gα in CB1(ACt)-Gi are shaded. One-letter 
coding for secondary structure: E, β-sheet; and H, α-helix. For the NMR structures, a phosphorylation-free 
peptide in DPC34, the Ser425Ct and Ser429Ct di-phosphorylated peptide in complex with β-arrestin-135 and 
Thr460Ct, Ser462Ct, Ser464Ct, Thr467Ct, and Ser468Ct multi-phosphorylated peptide in complex with β-
arrestin-136 were used. For the prediction, PredictProtein66 was used.
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Table 2
Intra- and inter-molecular interactions of CB1 Ct in the two distinct models ACt in CB1(ACt)-Gi and BCt in 
CB1(BCt)-Gi. Hydrophobic interactions involved by polar/charged residues occur through their aliphatic 
hydrocarbon portions, while H-bonding and salt bridge interactions involved by nonpolar residues occur 
through their backbone amides or the terminal carboxylates.
Model Intra-molecular (within CB1) Inter-molecular (with G protein)
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Table 3
Ligand binding and G protein coupling parameters for the wild-type CB1 receptor and the mutant receptors. 
Data are presented as the mean ± S.E. for the Ki values, basal levels and CP55,940-induced Emax values and 
the median and corresponding 95% confidence limits for the EC50 values, from at least three independent 
assays performed in duplicate.
CP55,940 Binding GTPγS Binding
Ki (nM)
Basal Levels CP55,940-induced
(fmol/mg) EC50 (nM) Emax (fmol/mg)
Wild type 1.8 ± 1.2 38.1 ± 0.6 2.2 ± (1.4-3.5) 55.3 ± 0.5
Glu416CtAla 1.9 ± 1.2 35.7 ± 1.5 1.0 (0.3-3.0) 52.6 ± 1.1
Asp423CtAla 3.6 ± 1.3 45.9 ± 1.3* 1.6 (0.8-3.1) 64.8 ± 0.7***
Asp428CtAla 2.5 ± 1.7 53.6 ± 2.7*** 1.0 (0.3-2.9) 68.5 ± 1.1***
Arg444CtAla 1.6 ± 1.2 31.7 ± 0.4 1.3 (0.7-2.4) 47.0 ± 0.6***
Asterisks depict the statistically significant differences in the GTPγS assay parameters compared to the wild-type CB1 receptor using analysis of 
variance followed by Bonferroni’s post hoc test:
*
, p < 0.05,
**
, p < 0.01,
***
, p < 0.001. No statistically significant differences were observed in Ki and EC50 values of any of the tested receptors from the wild-type CB1 
receptor.
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